Government publishes first ever medical technology strategy
Pharmafield Magazine
by Emma Cooper
19h ago
The Department of Health and Social Care has published the first ever medical technology (medtech) strategy, designed to ensure that patients across the UK can access safe, effective and innovative equipment and medical devices. Key aims of the strategy are to: Boost the supply of the best equipment to deliver greater resilience to health care challenges, such as pandemics, and enhance NHS performance through modernised technology which will enable faster diagnosis, treatment and ultimately discharge to free up hospital beds. Encourage ambitious, innovative research to secure the UK’s positio ..read more
Visit website
Ariceum Therapeutics appoints new Chief Medical Officer
Pharmafield Magazine
by Emma Cooper
5d ago
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has announced the appointment of Germo Gericke, M.D., as Chief Medical Officer. Germo joins Ariceum from Novartis, where he has recently served as Chief Medical Officer and Global Head of Research and Development at Advanced Accelerator Applications (AAA), a Novartis company specializing in the field of nuclear medicine. Germo will be based at Ariceum’s newly opened subsidiary in Basel, Switzerland.  Basel offers one of ..read more
Visit website
MHRA authorisation for AZ’s biliary tract cancer treatment  
Pharmafield Magazine
by Emma Cooper
6d ago
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC)1. This authorisation by the MHRA has been issued under Project Orbis, an international programme coordinated by the US Food and Drug Administration (FDA), which provides a framework for the concurrent submission and review of oncology medicines among international partners. Whi ..read more
Visit website
New ‘artificial pancreas’ technology could change the lives of those with type 1 diabetes
Pharmafield Magazine
by Emma Cooper
6d ago
People who are struggling to manage their type 1 diabetes could be offered new technology to help them control their condition with little human input. In draft guidance from the National Institute for Health and Care Excellence (NICE), a committee has recommended the use of hybrid closed loop systems for managing blood glucose levels in type 1 diabetes – technology that has been described as a step towards an artificial pancreas. Real world NHS trials has provided the data which has allowed NICE to consider wider use of the technology which allows a person with type 1 diabetes to go about the ..read more
Visit website
First CAR T-cell therapy recommended for routine use on NHS
Pharmafield Magazine
by Emma Cooper
1w ago
The National Institute for Health and Care Excellence (NICE) has recommended Gilead’s Yescarta® ▼ (axicabtagene ciloleucel; axi-cel) for routine commissioning on the NHS in England for the treatment of some adults with certain forms of lymphoma. Specifically, patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have already been treated with 2 or more systemic therapies may be eligible for treatment. Through the Cancer Drugs Fund, in 2018, England was the first country in Europe to provide access to a chimeric antigen receptor (CAR) T-ce ..read more
Visit website
New ABPI social media guidance released by PMCPA
Pharmafield Magazine
by Rhea Sethi
1w ago
The Prescription Medicines Code of Practice Authority (PMCPA) has published its first-ever social media guidance to help pharmaceutical companies apply the high standards demanded by the ABPI Code of Practice to all their online communications channels.   The PMCPA Social Media Guidance 2023 has been produced in consultation with the Medicines and Healthcare Products Regulatory Agency (MHRA), the ABPI, and pharmaceutical companies. It includes advice for companies to help them use social media in line with these rules and the rest of the Code.  The guide covers companies’ u ..read more
Visit website
ProPharma acquires Digital Lab Consulting
Pharmafield Magazine
by Emma Cooper
1w ago
ProPharma Group has announced the acquisition of Digital Lab Consulting (DLC) – a global premier advisory company specializing in digital transformation expertise and innovative solutions for life sciences organizations. The acquisition sees ProPharma further expand its global capabilities with the UK-based firm working across its full portfolio. Through the acquisition, ProPharma immediately expands its foundation of R&D technology services to include digital transformation, strategic roadmap development, system selection and high-level business analysis consulting. DLC has built a reputa ..read more
Visit website
NICE recommends Takeda’s rare blood cancer treatment
Pharmafield Magazine
by Emma Cooper
2w ago
The National Institute for Health and Care Excellence (NICE) has recommended Takeda’s NINLARO®▼ (ixazomib) with lenalidomide and dexamethasone as an option for treating relapsed or refractory multiple myeloma (RRMM) in adult patients who have received two or three lines of therapy, within a final appraisal document (FAD) published today.1 Multiple myeloma is a life-threatening rare blood cancer that arises from the plasma cells, a type of white blood cell that is made in the bone marrow.3 Nearly 6,000 people in the UK are diagnosed each year4 and at any one time, there are around 24,000 people ..read more
Visit website
NICE recommends Alnylam’s treatment for hereditary amyloidosis
Pharmafield Magazine
by Emma Cooper
2w ago
The National Institute for Health and Care Excellence (NICE) has published a draft decision recommending the use of AMVUTTRA® (vutrisiran) on the NHS in England as an option for treating hereditary transthyretin-related (ATTRv) amyloidosis.[ii] Vutrisiran, a subcutaneous injection administered once every three months, seeks to address the root cause of ATTRv amyloidosis by reducing the production of the abnormal protein (amyloid) that drives this disease. Following final guidance, patients will have the option of vutrisiran, meaning that many may now only need to visit the hospital for treatme ..read more
Visit website
AstraZeneca collaborates with AI tech team to speed up lung cancer diagnosis
Pharmafield Magazine
by Emma Cooper
2w ago
An initiative to improve earlier diagnosis of lung cancer has been launched by AstraZeneca UK, Qure.ai and Greater Manchester Cancer Alliance. The project will see an artificial intelligence system read 250,000 chest X-rays of people in Greater Manchester and evaluate whether the technology can support radiologists in making faster and more accurate diagnoses of lung cancer. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage, which could improve the patient’s quality of life and chances of survival.[i],[ii] The technology used by Qure.ai – called qXR ..read more
Visit website

Follow Pharmafield Magazine on Feedspot

Continue with Google
OR